[Efficacy of intravenous aspirin use in patients with acute coronary syndrome].
OBJECTIVE
To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS).


METHODS
ACS patients were randomly treated with intravenous aspirin (300 mg/d, IA, n = 30), low oral aspirin (100 mg/d, OA1, n = 32) or high oral aspirin (300 mg/d, OA2, n = 33). Aspirin sensitivity was tested by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA). The serum CD62p contents were examined by Flow cytometry.


RESULTS
Platelet aggregation expressed as ratio of reduction of ADP and AA post various aspirin were similar among 3 groups [IA: ADP (12.0 +/- 10.4)%, AA (6.7 +/- 11.2)%; OA1: ADP (6.0 +/- 14.6)%, AA (6.9 +/- 12.3)%; OA2: ADP (9.4 +/- 16.6)%, AA (7.3 +/- 13.0)%, all P > 0.05]. CD62p decreasing level post various aspirin were also similar among groups [IA: (10.9 +/- 18.6)%, OA1: (9.0 +/- 11.8)%, OA2: (7.1 +/- 15.7)%, all P > 0.05]. Side-effects and MACE post various aspirin use were comparable among groups.


CONCLUSIONS
Inhibiting efficacy on platelets function by intravenous aspirin (300 mg/d) was comparable to that of by oral aspirin (100 mg/d, 300 mg/d) in patients with acute coronary syndrome and could be used as an alternative route for patients who can't take oral aspirin.
Zhao
Yan
Y
Department of Cardiology, Capital University Affiliated Fuxing Hospital, Beijing 100038, China.
Shen
Lu-Hua
LH
Yang
Ming
M
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000188:drug therapy; D001241:Aspirin / Q000008:administration & dosage*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy
D001241:Aspirin